MedWatch

Analyst forecasts potential Novo Nordisk upgrade in strong second quarter outlook

Novo Nordisk is expected to stay on the tracks laid in the first quarter, when the pharmaceutical firm also raised its 2022 expectations significantly.

Photo: Novo Nordisk / PR

On Aug. 4, Novo Nordisk will reveal its second quarter figures, and Jyske Bank analyst Henrik Hallengreen Laustsen spies a guidance opportunity for the firm.

The senior analyst therefore expects that Novo Nordisk will maintain its first quarter momentum, which included new and improved expectations for the full year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs